WEP Clinical expands global CRO services with Siron Clinical acquisition

WEP Clinical (WEP), a global contract research organization (CRO) based in Morrisville, N.C., has acquired Siron Clinical, a Netherlands-based European CRO specializing in clinical operations for biotech companies.

As a full-service CRO, WEP designs, manages and executes clinical trials across multiple therapeutic areas, with a strong focus on proactive project management, scientific integrity, regulatory compliance and patient-centric execution.

The acquisition broadens WEP’s global footprint while strengthening its ability to deliver end-to-end Phase I–IV clinical trial solutions across complex, rare and specialized therapeutic areas.

“This acquisition represents a significant milestone in the evolution of our CRO services,” said Jaswinder Khera, WEP Founder and CEO. “By combining WEP’s global infrastructure with Siron Clinical’s deep operational expertise in complex and niche indications, we can offer sponsors seamless support from early-phase development through post-approval research.

Extending clinical operations

Founded in 2000, Siron specializes in clinical operations, including project management, clinical monitoring, quality assurance and regulatory submissions. In addition to its headquarters in the Netherlands, the company has offices in Belgium and Germany and employs clinical research professionals across Europe and the Middle East.

Siron has supported over 120 clinical studies, including those focused on orphan diseases, pediatric research and medical devices.

“Joining WEP gives our clients access to expanded services and global reach, while preserving the flexible, hands-on approach they value,” said Jan Balemans, Siron Founder and CEO. “We share WEP’s commitment to quality, transparency and patient-focused delivery, and together we will provide a more robust and scalable solution for biotech sponsors worldwide.”

Strengthening NC’s global reach

According to WEP, the acquisition will allow sponsors and research sites in N.C. to tap into a stronger full-service backbone across protocol and operational planning, regulatory strategy, start-up, site activation, patient recruitment support, study execution and close-out — helping complex trials move faster and more predictably.

“Bringing Siron’s extended European footprint into WEP expands our ability to coordinate truly global trials – allowing sponsors to plan and operate across the US, Europe and other global markets with one aligned team and one operational playbook, rather than stitching together multiple vendors,” said Khera. “This also strengthens the broader ecosystem, making North Carolina even more compelling as a place to build and scale clinical-stage companies, partnerships, and development programs.”